Abstract: Invention relates to new platinum (IV) complexes with substantially increased antitumor efficacy. A process for preparing said new platinum (IV) complexes is described. A pharmaceutical composition and a final dosage form for oral administration of the new platinum (IV) complexes is described. The use of the new platinum (IV) complex in a method to treat a tumor disease, preferably a heavy-to-treat cancer, most preferably pancreatic cancer, preferably by oral administration, is described.

Abstract: The invention relates to a new platinum (IV) complex with substantially increased antitumor efficacy. The invention further discloses a process for preparing of said complex and a pharmaceutical composition for the therapy of tumor diseases containing said complex.

Abstract: The invention relates to a new platinum (IV) complex with substantially increased antitumor efficacy. The invention further discloses a process for preparing of said complex and a pharmaceutical composition for the therapy of tumor diseases containing said complex.

Abstract: The present invention relates to a process for preparing a trichloroammineplatinate salt by reacting a tetrachloroplatinate salt in aqueous solution in the presence of ammonium chloride and an alkali chloride with one or more carbonate salts selected from the group consisting of potassium, sodium and ammonium carbonate while keeping the pH value below 7 during the reaction; the product obtained therein and a use thereof.

Abstract: The invention provides a process for preparing N-(hydrocarbyl)phosphoric or thiophosphoric triamides with substantially improved yields and purity. Two equivalents of hydrocarbylamine are used in the reaction with phosphoryl or thiophosphoryl chloride and then with ammonia in an aromatic solvent. The invention further relates to N-(hydrocarbyl)phosphopric or thiophosphoric triamides having the purity of at least 98% wherein R is a hydrocarbyl group and X is O or S. (RNH)(NH2)2P=X ??(I).

Abstract: The present invention relates to a process for preparing a trichloroammineplatinate salt by reacting a tetrachloroplatinate salt in aqueous solution in the presence of ammonium chloride and an alkali chloride with one or more carbonate salts selected from the group consisting of potassium, sodium and ammonium carbonate while keeping the pH value below 7 during the reaction; the product obtained therein and a use thereof.

Abstract: The invention provides a process for preparing N-(hydrocarbyl)phosphoric or thiophosphoric triamides with substantially improved yields and purity. Two equivalents of hydrocarbylamine are used in the reaction with phosphoryl or thiophosphoryl chloride and then with ammonia in an aromatic solvent. The invention further relates to N-(hydrocarbyl)phosphopric or thiophosphoric triamides having the purity of at least 98% wherein R is a hydrocarbyl group and X is O or S.

Abstract: The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ?-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical composition comprising (a) an effective amount of at least one taxane derivative, (b) an effective amount of at least one ?-3 poly-unsaturated fatty acid or a derivative thereof and (c) at least one pharmaceutically acceptable carrier and a process for the preparation of the same. The composition can be used for the therapy of cancers which are sensitive to taxane derivatives. The invention also relates to a kit comprising the individual components of the above mentioned composition placed in separate containers.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: A stabilized, injectable pharmaceutical composition for human administration comprises (a) an antineoplastic compound, (b) a solubilizing/dispersing agent, and (c) a stabilizing amount of an anti-oxidant.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ?-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical composition comprising (a) an effective amount of at least one taxane derivative, (b) an effective amount of at least one ?-3 poly-unsaturated fatty acid or a derivative thereof and (c) at least one pharmaceutically acceptable carrier and a process for the preparation of the same. The composition can be used for the therapy of cancers which are sensitive to taxane derivatives. The invention also relates to a kit comprising the individual components of the above mentioned composition placed in separate containers.

Abstract: The invention relates to a pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, wherein the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7. The invention also relates to the method of manufacturing of said composition and to the use of this composition in the treatment of tumors sensitive to oxaliplatin.

Abstract: The invention relates to a stabilised pharmaceutical composition comprising a pharmaceutically active substance poorly soluble in water, a solubilising agent with a low content of both basic and acidlic compounds and a polar organic solvent, in particular a stabilised injection concentrate, methods for preparing such stabilised pharmaceutical compositions and the use of a solubilising agent with a low content of both basic and acidic compounds to stabilise pharmaceutical compositions for pharmaceutically active substances.

Abstract: The invention concerns a pharmaceutical composition with antitumor activity based on carboplatin, comprising an aqueous solution of carboplatin with the carboplatin content from 1 to 20 mg·ml·−1. The pharmaceutical composition contains, immediately after its preparation, less than 0.1% by weight 1,1-cyclobutanedicarboxylic acid (“CBDCA”) and/or salt thereof, based on the weight of the present carboplatin.